approved the gene drug Kymriah for certain types of cancer. However, Kymriah costs $475,000 for one single treatment, Bloomberg reports, which is well beyond being affordable for average patients.
In the U.S., the FDA approval process itself adds billions of dollars to drug development costs, which pharmaceutical companies must then recover, and also adds years to the drug availability timeline. The impression that suffering U.S. patients are required to pay exorbitant drug prices to support over-regulation is difficult to escape.
In the U.S., the FDA approval process itself adds billions of dollars to drug development costs, which pharmaceutical companies must then recover, and also adds years to the drug availability timeline. The impression that suffering U.S. patients are required to pay exorbitant drug prices to support over-regulation is difficult to escape.